ArticleCombinatorial chemistry & high throughput screening2026
Shen-Ling-Bai-Zhu-San Mitigates Ulcerative Colitis by Enhancing Intestinal Barrier Integrity via the AhR-CYP1A1-NF-κB Signal Pathway.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionUlcerative Colitis (UC) represents a persistent inflammatory disorder of the colon, typically characterized by abdominal discomfort, diarrhea, and blood stools. Shen- Ling-Bai-Zhu-San (SLBZS), a traditional Chinese herbal formula, has shown clinical efficacy in alleviating symptoms such as abdominal bloating, frequent loose stools, and diarrhea. Nonetheless, the precise molecular mechanisms underlying its therapeutic effects remain largely unclear.
methodsUPLC-QE-MS combined with network pharmacology was employed to identify bioactive compounds and potential targets of SLBZS. A Dextran Sulfate Sodium (DSS)-induced colitis mouse model was used to evaluate its effects by monitoring changes in body weight, colon length, Disease Activity Index (DAI), inflammatory cytokines, oxidative stress markers, tight junction proteins, immunofluorescence, and histopathology. Molecular docking was used to predict the interaction of active compounds with UC-related targets, and Western blot analysis was performed to validate signaling pathways.
resultsSLBZS markedly improved DSS-induced colitis by restoring body weight, colon length, DAI, and histology. It suppressed pro-inflammatory cytokines and oxidative markers while enhancing antioxidant defenses. Expression of Occludin and Claudin-1 was recovered. UPLCMS/ MS identified 458 constituents, and network pharmacology revealed 98 potential targets enriched in NF-κB, TNF, and HIF-1 pathways. Validation experiments demonstrated the upregulation of AhR and CYP1A1 with concomitant downregulation of NLRP3 and IL-6. Molecular docking confirmed high-affinity interactions between key compounds and UC-related targets. DISCUSSION: These results indicate that SLBZS exerts its effects through anti-inflammatory and antioxidant mechanisms while strengthening the intestinal barrier, reflecting its multi-target therapeutic potential.
conclusionsSLBZS alleviates UC by regulating the AhR-CYP1A1-NF-κB axis, suppressing inflammation, and maintaining mucosal barrier function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.